Navigation Links
Echo Healthcare Extends Stockholder Vote on Proposed Merger With XLNT Veterinary Care to January 4, 2008
Date:12/28/2007

conversion rights must complete the procedures set forth in the supplement dated November 26, 2007 before 5:00 p.m., New York time on January 3, 2008. If you have previously sent in a proxy card, you do not need to send another card unless you desire to change your vote.

The Board of Directors of Echo unanimously recommends that stockholders vote "for" each of the proposals related to the proposed merger transaction. Additional information about the proposed merger and each of the other proposals can be found in the definitive proxy statement/prospectus and supplement. A definitive proxy statement/prospectus relating to the special meeting was filed with the Securities and Exchange Commission (the "SEC") on November 13, 2007 and a subsequent supplement to that proxy statement/prospectus was filed with the SEC on November 27, 2007. The supplement and the entire proxy statement/prospectus are also available at the Company's website at http://www.echohealthcare.com and as filed at http://www.sec.gov.

About Echo Healthcare Acquisition Corp.

Echo Healthcare Acquisition Corp. is a blank check company that was formed on June 10, 2005 to serve as a vehicle for the acquisition of one or more domestic or international operating businesses in the healthcare industry. On March 22, 2006, Echo consummated its initial public offering ("IPO") of 6,250,000 Units. On March 27, 2006, the Company consummated the closing of 937,500 additional Units subject to the underwriters' over-allotment option. The 7,187,500 Units sold in the IPO (including the 937,500 Units subject to the underwriters' over-allotment option) were sold at an offering price of $8.00 per Unit, which together with the private placement of the 458,333 warrants to certain stockholders and directors of the Company at an offering price of $1.20 per share, generated total gross proceeds of $58,050,0
'/>"/>

SOURCE Echo Healthcare Acquisition Corp.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. AtriCure to Present at Thomas Weisel Partners 2007 Healthcare Conference
2. BD to Present at the Bear Stearns 20th Annual Healthcare Conference
3. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
4. Dr. Paul Bandt Celebrates 35th Anniversary With Desert Radiologists and a History of Healthcare in Las Vegas
5. Omnicell to Present at Thomas Weisel Healthcare Conference 2007
6. MDS to Present at Thomas Weisel Partners Healthcare Conference
7. Hospira to Present at the Bear Stearns 20th Annual Healthcare Conference on September 11
8. AMICAS to Present at Thomas Weisel Partners Healthcare Conference 2007
9. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
10. Kingfisher Healthcare (KFH) Achieves World Class Quality Platform
11. Omnicom Acquires Leading Healthcare Marketing Communications Firm in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2014)... policymakers consider ways to ease prohibitions on marijuana, the ... over the past century may provide valuable lessons, according ... that legalized marijuana in Colorado and Washington for recreational ... how to best allow the production, sales and the ... related social ills. , A new study published online ...
(Date:4/20/2014)... Researchers may have identified key genes linked to why ... others, according to a study released today that will ... Annual Meeting in Philadelphia, April 26 to May 3, ... it provides an objective way to understand pain and ... study author Tobore Onojjighofia, MD, MPH, with Proove Biosciences ...
(Date:4/18/2014)... The Gerontologist reports that among older Christians, ... in anxiety about death and increases in life satisfaction, ... particular, listening to gospel music is associated with a ... sense of control. , These associations are similar for ... both low- and high-socioeconomic status. , The article, titled ...
(Date:4/18/2014)... Benaroya Research Institute at Virginia Mason (BRI) recently received ... in metastatic breast cancer reduces both the growth of ... scientists have found in models of the disease that ... 80 percent and can keep the tumor from metastasizing ... grant comes from the National Cancer Institute of the ...
(Date:4/18/2014)... by Northwestern Medicine scientists could lead to potential new ... people with scleroderma. , Fibrosis, or scarring, is ... the skin and lungs can lead to serious organ ... for new therapeutic options centers on findings made by ... identified the role that a specific protein plays in ...
Breaking Medicine News(10 mins):Health News:Regulating legal marijuana could be guided by lessons from alcohol and tobacco, study says 2Health News:Low tolerance for pain? The reason may be in your genes 2Health News:Religious music brings benefit to seniors' mental health 2Health News:Benaroya Research Institute evaluates immunology approach to blocking breast cancer 2Health News:New clues on tissue scarring in scleroderma 2
... that only 2 in 5 seek any assistance, ... being,one of today,s most common disorders, it is regularly ... occasional feelings of anxiety -- muscle tension,headache, nausea, fatigue, ... speaking, first dates, or during times of stress such ...
... Diseases (NIAID), part of the National Institutes of ... Clinical Proteomics Centers for Infectious Diseases and Biodefense. ... Texas Medical Branch (UTMB), Galveston, and to the ... centers will analyze human blood and other tissue ...
... launch anticipated in early 2009 -, CORONA, ... WPI ), a leading specialty pharmaceutical,company, announced today ... approved RAPAFLO(TM) (silodosin), the company,s new alpha blocker ... BPH., BPH is the number one reason ...
... Celestial,Group, Inc. (Nasdaq: HAIN ), a leading ... today announced that Irwin Simon, President and,Chief Executive ... the,Company on Wednesday, October 15, 2008 at the ... http://www.newscom.com/cgi-bin/prnh/20050324/NYTH131 ), The investor presentation ...
... Robbins & Myers, Inc.,(NYSE: RBN ) ... a regular,cash dividend payment of $0.0375 per share. ... shareholders of record as of October 20, 2008., ... supplier of engineered equipment and,systems for critical applications ...
... Oct. 8 New physical activity guidelines,released today ... Services (HHS),will give Americans the information they need ... of the USA, the national resource office for ... Activity Guidelines for Americans set achievable,goals for everyone ...
Cached Medicine News:Health News:40 Million Americans Endure Anxiety Everyday 2Health News:NIAID awards contracts to search for protein markers of disease 2Health News:Watson Receives US FDA Approval for RAPAFLO(TM) (silodosin) for the Treatment of Benign Prostatic Hyperplasia (BPH) 2Health News:Watson Receives US FDA Approval for RAPAFLO(TM) (silodosin) for the Treatment of Benign Prostatic Hyperplasia (BPH) 3Health News:Watson Receives US FDA Approval for RAPAFLO(TM) (silodosin) for the Treatment of Benign Prostatic Hyperplasia (BPH) 4Health News:Hain Celestial to Present at Canaccord Adams Healthy Living Naturally Boston Conference on October 15, 2008 2Health News:YMCA of the USA Supports New National Physical Activity Guidelines 2
(Date:1/15/2014)... Therapeutics, Inc. (Nasdaq: ECTE ) ("Echo"), a ... a non-invasive, wireless continuous glucose monitoring system, today announced ... Interim CEO of Echo Therapeutics, will present at "TEN", ... Mr. Doman will make a corporate presentation ...
(Date:1/15/2014)... 2014 Reportlinker.com announces that a new ... catalogue: PharmaPoint: Atopic ... Analysis to 2022 http://www.reportlinker.com/p01957657/PharmaPoint-Atopic-Dermatitis---India-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology ... India Drug Forecast and Market Analysis to ...
(Date:1/15/2014)... Jan. 15, 2014  Zafgen, Inc., a leading biopharmaceutical ... severely obese patients, today announced initial results from ... inhibitor of methionine aminopeptidase 2 (MetAP2), in patients ... genetic obesity.  These results showed improvements in body ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
... Argos Therapeutics announced today that interleukin ... dendritic cell (DC) immunotherapy and can be used as a ... company,s lead product, AGS-003, in metastatic renal cell carcinoma (mRCC). ... Immunotherapy demonstrate that the potency of mature CD40L RNA electroporated ...
... Rotational molder REMCON Plastics is already seeing process reduction ... organized under the leadership of new hire Benjamin F. ... REMCON,s Lean Manufacturing and Continuous Improvement Initiatives. He will ... active teams to sustain a strong, lean culture within ...
Cached Medicine Technology:Interleukin (IL)-12 Secretion Can Predict Potency of Argos Therapeutics' Arcelis™ Dendritic Cell (DC) Immunotherapy and Can Be Used as Potency Marker in Phase 3 Clinical Trial 2Interleukin (IL)-12 Secretion Can Predict Potency of Argos Therapeutics' Arcelis™ Dendritic Cell (DC) Immunotherapy and Can Be Used as Potency Marker in Phase 3 Clinical Trial 3Six Sigma Black Belt and Lean Sensei Ben Wittich Joins REMCON Plastics 2
Double-ended. Designated most popular model or size....
Designated most popular model or size. 3 mm tip....
Octagonal handle. 3 mm wide....
4 mm x 6 mm dissector end with shaft marked at 10 mm, 20 mm, 30 mm from tip. 6 mm wide curved elevator. Round knurled handle....
Medicine Products: